Product Images Losortan Potassium

Losartan Potassium is a prescription drug that is available in the form of tablets. The package contains 50 tablets in a unit dose of 5 X 10. Each tablet contains 25mg of Losartan Potassium USP. The usual dosage details are available in the package insert. The tablets should be stored at 20-25°C (68° to 77°F) in a controlled room temperature condition, protected from light. It is important to keep all medications, including Losartan Potassium, out of the reach of children. This medication is manufactured by Avkare and it is Rx-only.*

Losartan Potassium Tablets USP is a prescription-only medication that contains 50 mg of losartan potassium. The package contains 50 tablets (5 x 10 unit dose) and should be stored at a controlled room temperature protected from light. The manufacturer is AVKARE, located in Pulaski, TH 38475. Patients should consult with their physician for complete prescribing information.*

This is a description of a medication called Losartan Potassium in tablet form with a dosage of 100mg per tablet. The medication is only available through a prescription, and each pack comes with 50 tablets. The box contains the National Drug Code (NDC) number which is 50268-506-15. The medication is stored between 20 to 25 degrees Celsius and must be protected from light. The usual dosage is advised through a package insert, and it is recommended to keep the medication out of reach of children. The text also includes a reference to a company named Avkare.*

This appears to be a chart or graph related to a study comparing the effectiveness of two drugs, Atenolol and Losartan Potassium. The chart mentions a percentage related to the primary endpoint of the study and an adjusted risk reduction of 13%, with a p-value of 0.021. There are also time intervals represented on the chart, ranging from 18 to 66 months, suggesting that the study was conducted over a period of several years.*

This is a table showing the percentage of patients who experienced fatal/non-fatal stroke while taking Atenolol and Losartan Potassium. The table also indicates an adjusted risk reduction of 25% with a p-value of 0.001. The study was conducted over a period of 66 months.*

Not available. The given text appears to be a few errors and random characters and doesn't convey any coherent information.*

The text appears to be a table showing the percentage of patients with an event, risk reduction, and p-value for Losartan Potassium Tablet and Placebo. However, without additional context, it is difficult to determine the specific details of the study or what the numbers represent.*